← Back to patent-cliff list
Nangibotide
Tier C — Watch / tradeNangibotide
Inotrem
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TREM1
Brand：Motrem
Indications (approved)：COVID-19, 感染性休克
Regional status
US
-
EU
Phase II
2017-07-03
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nangibotide?
Approved indications include: COVID-19, 感染性休克.
When does the Nangibotide patent expire?
No public expiry year is available for Nangibotide yet; this page updates once verified.
How do I get a quote for Nangibotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09